I see the future and the future is bright indeed.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$ISOLF looking good this morning.
News just went out on $ISOLF
VANCOUVER, British Columbia, March 12, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive CBD innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce that the Company has successfully performed all of the due diligence set out in the binding agreement to acquire the Biosynthesis Pharma Group (BSPG). With this process now complete, the Company anticipates the closing of the acquisition to occur within the next couple of weeks.
Through BSPG’s proprietary industrial scale extraction methodologies, the company produces a high-purity, bioactive CBD isolate at a purity level of 99.5%+ for use in pharmaceutical applications globally to benefit humans and animals suffering from a range of both critical and non-life-threatening illnesses. BSPG currently has the capability of processing over 1.5 metric tons of hemp biomass daily to extract CBD, terpenes and other cannabinoids, specifically CBG.
“Isodiol management and legal teams have done a tremendous job vetting and validating all operating and financial information of the BSPG companies”, stated Marcos Agramont, CEO of Isodiol International Inc. “With this acquisition closing imminently, we will control manufacturing of the world’s purest, most bioactive CBD isolate, and will control a true pharmaceutical grade CBD product that is backed by clinical data from world renowned institutions. The BSPG team has done an incredible job establishing its global operations and with this merger, we are now positioned to change the conversation around the world on CBD and other cannabinoids.”
As the acquisition closes, the Company will begin publishing the various findings from clinicals completed using the BSPG CBD isolate. Publishing this data will coincide with implementing commercialization strategies for the various markets this clinical data can be represented. Teams are currently being assembled in these countries with practitioner education seminars and establishing logistics being the focus.
“The education process needs to start at the government regulator and practitioner levels and Isodiol is committed to this process through various initiatives”, stated Marcos Agramont. “Through our partnership with Livecare we are assembling a team of world-class doctors, researchers and industry professionals in collaborating on research which will be shared through the Livecare interface for the public to access.”
There have been no changes to the acquisition price stated in the news release from December 17th, 2017.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol’s growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
$IMLFF and $ISOLF are the 2 Top CBD Companies in the sector right now.
About InMed Pharmaceuticals Inc.
InMed is a preclinical-stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics platform, its biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.
We seek Safe Harbor.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of CBD consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of over 99-per-cent-pure, bioactive pharmaceutical grade cannabinoids, microencapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
Congrat's to all $IMLFF Shareholders!
Isodiol International Inc.
Isodiol International Inc. (ISOLF) hit an upwards weekly price breakout.
24 minutes ago
$ISOLF is starting to Look better today, the volume has been increasing over the last several days here.
Have a look at $IMLFF, they are an up and coming CBD company but currently have zero revenue or any products in the pipeline as of yet and their SP is soaring at the moment.
These are still very early days in the sector right now and $ISOLF is one of only a handful of companies that are making any type of revenue right now.
The Top 2 up and coming #CBD Companies IMHO are $IMLFF and $ISOLF.
I love what an amazing company $IMLFF is, congrats for all you long time shareholders who have always believed in this company.
Also here's a brief run down on the other CBD company that I mentioned earlier.
www.isodiol.com
About Isodiol International
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Here's an Article that was written up on $ISOLF by 420 this morning.
Earnings season is coming to a close and cannabis companies have been reporting much stronger numbers on a year-over-year basis. When it comes to considering a company as a potential long-term opportunity, two trends you want to see are improving fundamentals and continued execution.
One company that meets this criteria is Isodiol International Inc. (ISOL:CNX) (ISOLF). The company is a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and nutraceutical products.
We are favorable on Isodiol due to its strategic partnership with leading cannabis companies such as Canopy Growth (WEED:APH) (TWMJF), Nuuvera (NUU:APH) and Namaste Technologies (N:CNX) (NXTTF), as well as its continued execution where Isodiol remains laser focused on increasing its global footprint.
Quarterly Numbers Show Strong Growth
Last week, Isodiol released third quarter financial and operating results. During the quarter, the CBD innovator generated almost $6 million in revenue which is incrementally higher than the same period last year.
Isodiol attributed the growth and profit increase to greater distribution, reduced manufacturing costs, portfolio diversification, and the continued integration of wholly owned subsidiaries.
Over the last year, Isodiol has been nothing short of an execution story and has become a global CBD leader. During this time, the company expanded operations and has continued to gain traction in international markets such as Latin America and Europe.
Isodiol has made some significant announcements over the last quarter and during this time, the company has strengthened its balance sheet by completing a $30 million non-brokered private placement at $1.25 per unit.
The stronger balance sheet allows Isodiol to continue to pursue additional global growth opportunities. The company has also made significant traction in operations with wholly owned subsidiaries such as ISO-Sport, Be Tru Wellness, and Bradley’s Bioscience, which provides several catalysts for growth.
Isodiol Secures Two Strategic Canadian Partners
Among the most significant developments in 2018 have been the strategic partnerships that Isodiol has entered into. During this time, the company has announced a LOI with Nuuvera (NUU.V) pertaining to importing CDB as well as a supply agreement with Namaste Technologies (N.CN) (NXTTF).
Isodiol and Nuuvera have agreed to import 99%+ pure, bioactive pharma-grade CBD isolate into Canada from Isodiol’s GMP-certified production facility in the United Kingdom. The product will be imported into Canada through Nuuvera’s subsidiary, ARA - Avanti Rx Analytics Inc., a Health Canada GMP-certified laboratory holding a dealer license.
The agreement with Namaste, is mutually beneficial for both companies. The agreement offers a new domestic and international sales channel for Isodiol to distribute its products and adds significant value to Namaste’s product offering on a global scale. Namaste intends to distribute the products in regional markets where cannabinoid products are available.
Continues to Expand Via Organic and Inorganic Growth Initiatives
Isodiol continues to grow through organic and inorganic growth initiatives. We are favorable on this multi-faceted growth strategy and will monitor the impact it has on revenue numbers over the coming quarters.
In mid-January, Isodiol signed a LOI to acquire 100% of the CBD assets of Green Island Naturals, a formulator, marketer and seller of a proprietary line of hemp extract products that are distributed in retail and online channels in Canada. In 2017, the company generated $2 million in revenues and with the support of Isodiol expects to see exponential growth this year.
In late 2017, Isodiol entered a binding agreement to acquire the Biosynthesis Pharma Group (BSPG), an industry leading producer of industrial hemp. Through BSPG’s proprietary extraction methodologies, the company produces cannabinoids that are used in pharmaceutical applications. From Hong Kong to Austria and from China to the U.K., BSPG is comprised of multiple entities that will benefit Isodiol.
In early December, Isodiol entered a binding agreement to acquire Be Tru Organics, a formulator, marketer, and seller of a proprietary line of hemp extract products. Shortly after completing the acquisition, Be Tru Organics started the process of distributing products to Erewhon Natural Foods, a supermarket chain in California that has been providing organic foods and products to consumers since the late 1960s.
With the recent capital raise, Isodiol is well positioned to grow these strategic assets and build on the existing revenue streams. We expect these acquisitions to prove to be accretive and are favorable on the strategy.
Continues to Execute and Deliver Results
When we analyze marijuana companies, we look for companies that are executing on previously announced initiatives. This is important because many cannabis companies simply just release news for a short-term spike.
Isodiol is a company that continues to execute on previously announced initiatives and is led by a management team with a proven track record. We are favorable on these traits and believe investors need to keep an eye on Isodiol.
Isodiol has been laser focused when it comes to executing on initiatives, raised capital at $1.25 per unit, and is trading below this level. Despite the recent announcements, Isodiol has been under pressure in 2018 and the shares are down more than 20%.
This pullback has created a great opportunity for new and existing investors. We think the recent developments have Isodiol positioned for significant growth and will keep an eye on how the shares move from here.
$ISOLF News just out and this one is impressive!
Isodiol International Inc. Receives Regulatory (ANVISA) Approval for Isodiolex for the Treatment of Epilepsy and Parkinson’s
PRESS RELEASE GlobeNewswire
Feb. 5, 2018, 10:00 AM
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has received approval from the Brazilian Health Regulatory Agency (ANVISA) This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. This is now the Company’s second product to receive medical approval by the ANVISA.
“We have been working towards additional products for the Brazilian medical community and for the last several months, so to have our second product medically approved by ANVISA is a tremendous breakthrough for the company,” said CEO of Isodiol, Marcos Agramont. “We have been working with neurologists and medical practitioners to offer an alternative delivery method of cannabidiol and Isodiolex is the perfect solution for this. Overall, we will continue to be proactive in increasing our global footprint, especially where cannabinol is medically approved, affording us the opportunity to truly show how cannabinol is beneficial for the human body.”
Additional information around Isodiolex will be provided in the coming weeks.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
$ISOLF News Just out and this one is very impressive.
Isodiol International Inc. Receives Regulatory (ANVISA) Approval for Isodiolex for the Treatment of Epilepsy and Parkinson’s
PRESS RELEASE GlobeNewswire
Feb. 5, 2018, 10:00 AM
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has received approval from the Brazilian Health Regulatory Agency (ANVISA) This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. This is now the Company’s second product to receive medical approval by the ANVISA.
“We have been working towards additional products for the Brazilian medical community and for the last several months, so to have our second product medically approved by ANVISA is a tremendous breakthrough for the company,” said CEO of Isodiol, Marcos Agramont. “We have been working with neurologists and medical practitioners to offer an alternative delivery method of cannabidiol and Isodiolex is the perfect solution for this. Overall, we will continue to be proactive in increasing our global footprint, especially where cannabinol is medically approved, affording us the opportunity to truly show how cannabinol is beneficial for the human body.”
Additional information around Isodiolex will be provided in the coming weeks.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
$ISOLF News and this one is impressive.
Isodiol International Inc. Receives Regulatory (ANVISA) Approval for Isodiolex for the Treatment of Epilepsy and Parkinson’s
PRESS RELEASE GlobeNewswire
Feb. 5, 2018, 10:00 AM
VANCOUVER, British Columbia, Feb. 05, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that it has received approval from the Brazilian Health Regulatory Agency (ANVISA) This product will be placed on the Special Category List for alternative therapies which will enable it to be prescribed by doctors and neurologists. This is now the Company’s second product to receive medical approval by the ANVISA.
“We have been working towards additional products for the Brazilian medical community and for the last several months, so to have our second product medically approved by ANVISA is a tremendous breakthrough for the company,” said CEO of Isodiol, Marcos Agramont. “We have been working with neurologists and medical practitioners to offer an alternative delivery method of cannabidiol and Isodiolex is the perfect solution for this. Overall, we will continue to be proactive in increasing our global footprint, especially where cannabinol is medically approved, affording us the opportunity to truly show how cannabinol is beneficial for the human body.”
Additional information around Isodiolex will be provided in the coming weeks.
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
No sir, I am not. Is he talking about the company at the moment?
$ISOLF
ORIGINAL: Isodiol International Inc. Brand Ambassador and Spokesman to Discuss CTE at Superbowl LII
2018-01-29 13:25 ET - News Release
VANCOUVER, B.C., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTC: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”), a global Bioactive Phytoceutical innovator specializing in the development of pharmaceutical and wellness products, announced today that Marvin Washington, brand ambassador and spokesman for Isodiol, will be speaking on the cause of the neurological disorder Chronic Traumatic Encephalopathy (CTE) at Super Bowl LII.
Mr. Washington will be in Minneapolis before the Super Bowl to draw attention to the silent killer of football players in the National Football League. Together, through the Company’s brand ISO-Sport, the goal is to raise awareness about CTE and the dangers of player concussions.
“Players are dying from CTE,” said Mr. Washington, a defensive end in the National Football League for eleven seasons, 1989-1999. “I want to sound the alarm about CTE, and let the world know there is a way to protect the brains of players and stop the damage with CBD.”
In an interview with i24NEWS, Mr. Washington added, “The US government has a patent that says a cannabinoid in a cannabis plant can be used as an antioxidant or protective for the brain and that is what I take. The leading cannabidiol company in the world is Isodiol and I have aligned with them, and we have taken this all the way to the body that represents the former players, which is the National Football League Players Association.”
To view this interview from January 26, 2018, please visit http://www.i24news.tv/en/tv/replay/stateside/x6drk72.
Mr. Washington, who won a Super Bowl ring with the Denver Broncos in 1999, is now a crusader for the healing powers of cannabis with Isodiol. The company is actively developing non-psychoactive cannabinoids to work as neuroprotectants for athletes on the football field.
“This is a matter of life and death,” said Mr. Washington. “The science is there. The proof is there. We need to protect players, and I believe Cannabidiol – “CBD” is the solution.”
For more information on Isodiol, please visit www.isodiol.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
MarcosAgramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
$ISOLF News just out.
: Isodiol International Inc. Brand Ambassador and Spokesman to Discuss CTE at Superbowl LII
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2562550&symbol=ISOL®ion=C
$ISOLF News just out
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2561919&symbol=ISOL®ion=C
ISODIOL INTERNATIONAL INC. ANNOUNCES LICENSING AGREEMENT WITH LIVECARE HEALTH CANADA INC. AND APPOINTS DR. AMIT MATHUR TO MEDICAL ADVISORY BOARD
Isodiol International Inc. has signed a licencing agreement with Livecare Health Canada Inc., an organization founded and operated by doctors dedicated to giving patients access to quality, real-time health care, regardless of where they are located.
Livecare is a Vancouver-based company committed to empowering health care through technology. Founded by Dr. Mark Godley in 2012, it offers digital technologies that connect doctors and allied health care providers to their patients via secure, encrypted, face-to-face video and messaging.
Under the terms of the licencing agreement, Isodiol will license the Telehealth platform and operate it under a white label in connection with the marketing of all its products. The licence shall grant Isodiol the exclusive right to use the platform relating to all cannabis, cannabis-derived, cannabinoid and phytoceutical products, and related services. Livecare will customize and convey the platform for Isodiol and will assist in marketing and commercializing the platform on a global scale.
The platform is generally described as an interconnectivity network with a cloud-based user interface that provides access by multiple categories of users, including patients, physicians, other medical professionals, pharmaceutical providers and on personal computing devices to deliver health and wellness solutions without regard to the physical location of the users.
"Isodiol is extremely proud of this innovative step, where our consumers will now have the ability to consult with medical experts via the Telehealth platform technology," said chief executive officer of Isodiol, Marcos Agramont. "Our customers are extremely valued and consumers around the globe, particularly in urban areas, will now face little to no inconveniences when seeking health and wellness improvement."
As a part of the licencing agreement, the company will pay Livecare a royalty dependant on the jurisdiction of commercialization. The company will also issue four quarterly installments of stock in the first year of $250,000 which will be subject to a 36-month escrow schedule.
In addition to the licencing agreement, Isodiol has appointed Dr. Amit Mathur, co-founder of Livecare, as a medical adviser to the company with focus on implementing a global strategy for the commercialization of the platform.
Over the years, Dr. Mathur has lectured on behalf and participated on national advisory boards to multiple pharmaceutical companies. He has a passion for rural healthcare and has participated in international conferences and seminars in Asia as an adviser and keynote speaker on rural eye health delivery. He bridges his health care and clinic operations experience with his business consulting background to be uniquely effective.
"We are excited to welcome Dr. Mathur to the Isodiol family and we are confident that he will be a valuable addition to the team," said Mr. Agramont. "Dr. Mathur will play a valuable role in ensuring communities and rural municipalities will receive greater access to physicians and allied health providers."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99 per cent plus pure, bioactive pharmaceutical grade cannabinoids, microencapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
This is very positive news this am.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2561919&symbol=ISOL®ion=C
ISODIOL INTERNATIONAL INC. ANNOUNCES LICENSING AGREEMENT WITH LIVECARE HEALTH CANADA INC. AND APPOINTS DR. AMIT MATHUR TO MEDICAL ADVISORY BOARD
Isodiol International Inc. has signed a licencing agreement with Livecare Health Canada Inc., an organization founded and operated by doctors dedicated to giving patients access to quality, real-time health care, regardless of where they are located.
Livecare is a Vancouver-based company committed to empowering health care through technology. Founded by Dr. Mark Godley in 2012, it offers digital technologies that connect doctors and allied health care providers to their patients via secure, encrypted, face-to-face video and messaging.
Under the terms of the licencing agreement, Isodiol will license the Telehealth platform and operate it under a white label in connection with the marketing of all its products. The licence shall grant Isodiol the exclusive right to use the platform relating to all cannabis, cannabis-derived, cannabinoid and phytoceutical products, and related services. Livecare will customize and convey the platform for Isodiol and will assist in marketing and commercializing the platform on a global scale.
The platform is generally described as an interconnectivity network with a cloud-based user interface that provides access by multiple categories of users, including patients, physicians, other medical professionals, pharmaceutical providers and on personal computing devices to deliver health and wellness solutions without regard to the physical location of the users.
"Isodiol is extremely proud of this innovative step, where our consumers will now have the ability to consult with medical experts via the Telehealth platform technology," said chief executive officer of Isodiol, Marcos Agramont. "Our customers are extremely valued and consumers around the globe, particularly in urban areas, will now face little to no inconveniences when seeking health and wellness improvement."
As a part of the licencing agreement, the company will pay Livecare a royalty dependant on the jurisdiction of commercialization. The company will also issue four quarterly installments of stock in the first year of $250,000 which will be subject to a 36-month escrow schedule.
In addition to the licencing agreement, Isodiol has appointed Dr. Amit Mathur, co-founder of Livecare, as a medical adviser to the company with focus on implementing a global strategy for the commercialization of the platform.
Over the years, Dr. Mathur has lectured on behalf and participated on national advisory boards to multiple pharmaceutical companies. He has a passion for rural healthcare and has participated in international conferences and seminars in Asia as an adviser and keynote speaker on rural eye health delivery. He bridges his health care and clinic operations experience with his business consulting background to be uniquely effective.
"We are excited to welcome Dr. Mathur to the Isodiol family and we are confident that he will be a valuable addition to the team," said Mr. Agramont. "Dr. Mathur will play a valuable role in ensuring communities and rural municipalities will receive greater access to physicians and allied health providers."
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99 per cent plus pure, bioactive pharmaceutical grade cannabinoids, microencapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
$ISOLF is Ranked number 6, in their Cannabis Company Revenue Ranking. Here's the Link Below.
https://www.newcannabisventures.com/cannabis-company-revenue-ranking/
Sorry that was the wrong news here's $CHOOF's News from this morning.
CHOOM(TM) ANNOUNCES RETAIL DISPENSARY CONCEPT DESIGN
Choom Holdings Inc. has provided its retail dispensary strategy with its new concept retail store design. ChoomTM aims to be a market leader in the reaching the Canadian cannabis consumer. Choom intends to develop a chain of branded retail cannabis dispensaries in jurisdictions in Canada where the private distribution of recreational cannabis is legalized.
Chris Bogart, President & CEO, states, "As the Canadian market approaches a new cannabis recreation marketplace, meeting consumer perception and choice with social credibility will be key."
ChoomTM is a brand created exclusively for the recreational market, core to our values is cultivating a great experience for the consumer and part of this strategy is retail distribution. Retail identity and branding will become our competitive edge, so we hired the design team responsible for some of the most recognized retail environments in Canada to bring the Choom vibe to life.
"We wanted to create a retail experience for ChoomTM that measured up to stores in any industry. We wanted to be able to translate the brand into a welcoming physical and operational environment. Immersive store design will be critical to retail success in an industry destined for explosive growth" states, Juli Hodgson, President Hodgson Design Associates.
SAY HELLO TO CHOOMTM
Choom(TM) was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970's who loved to smoke weed-or as the locals called it, "Choom". Now, after four decades, ChoomTM is bringing the spirit of Hawaii to the Okanagan and Canada. We're planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb.
We seek Safe Harbor.
$CHOOF News out
ISODIOL INTERNATIONAL INC. ANNOUNCES EXTENSION OF LICENSING AGREEMENT WITH KATHY IRELAND AND LEVEL BRANDS
Isodiol International Inc. has signed an amendment to the licence agreement with Level Brands Inc. The amended agreement extends the terms from five years to 10 years and expands the territorial coverage from North America to worldwide. The amendment was entered into after both parties concluded discussions contemplated under the terms of the agreement.
Marcos Agramont, chief executive officer of Isodiol, said: "Upon further discussion with Kathy Ireland and the Level Brands team, it became clear that both sides share a common goal, which is to help people around the globe understand how cannabidiol is beneficial for the human body. With this expanded agreement, we will now be able to introduce a variety of Isodiol brands to Kathy's extremely large network around the globe. Over all, Level Brands is innovative in licensing, marketing and brand management, and this will further assist Isodiol in providing consistent and highly bioactive products. The opportunity to increase this partnership from North America to worldwide is something that we believe will have a tremendous impact on Isodiol in the short and long term."
Kathy Ireland, chairman emeritus and chief brand strategist of Level Brands, said: "Our vision is that Isodiol will become the leading CBD company in the world. The CBD market is at its infancy, and we believe, based on our research and decades of brand building, that the CBD industry will see enormous growth over the next decade on a worldwide basis. We look forward to working with the Isodiol team to execute on a multifaceted marketing strategy that we feel will enable Isodiol to grow its bulk and private label businesses, as well be able to rapidly go to market with specialized branded lines of unique and best-in-class products."
The Isodiol product portfolio will include body balms, tinctures, personal care, nano-mist and functional beverages.
Martin Sumichrast, chairman and chief executive officer of Level Brands, also added: "We believe that the technology that the Isodiol team has acquired and is acquiring will allow Isodiol to be at the forefront of the CBD industry. Our companies have embarked on a decade-long partnership which has the potential to not only sell consumer branded products worldwide, but also bring to market new innovative means I believe will provide consumers the benefits of CBD. We are incredibly grateful for this opportunity and the leadership that Kathy and the team at kathy ireland worldwide has and will provide to Level Brands and the team at Isodiol."
No additional consideration was issued for the expanded territorial coverage from North America to worldwide.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99 per cent plus pure, bioactive pharmaceutical grade cannabinoids, microencapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
© 2018 Canjex Publishing Ltd. All rights reserved.
Finally $ISOLF closes back in the Green, hopefully this is the trend from now on.
Great write up from TheSeedInvestor on $CHOOF
http://theseedinvestor.com/cannabis-news/how-these-canadian-companies-are-preparing-for-potential-6-billion-market
$ISOLF News just out!
ISODIOL INTERNATIONAL INC. ANNOUNCES LETTER OF INTENT TO IMPORT 99%+ PURE PHARMA-GRADE CANNABIDIOL TO CANADA FROM U.K. WITH NUUVERA
Isodiol International Inc. has signed a letter of intent with Nuuvera Holdings Ltd.
Isodiol and Nuuvera have agreed to import plus-99-per-cent-pure, bioactive pharma-grade cannabidiol isolate into Canada from Isodiol's GMP-certified production facility in the United Kingdom. The product, certified as a pharmaceutical grade, will be imported into Canada through Nuuvera's subsidiary, ARA -- Avanti Rx Analytics Inc., a Health Canada GMP-certified laboratory holding a dealer licence under the Narcotic Control Regulations and Office of Controlled Substances.
"Since establishing Isodiol, we have focused on developing and marketing the highest-quality, raw material for use in a range of proprietary, pharma-grade nutritional and health-related remedies," said Isodiol chief executive officer Marcos Agramont. "We are very pleased that our new partner, Nuuvera, which brings to the table extensive knowledge and expertise in the fields of quality control, cannabis extraction, purification, product development and R&D, shares Isodiol's vision for an industry built upon quality, consistency, safety and ultimately, efficacy. Isodiol and Nuuvera are at the global forefront of innovation in the cannabis industry, and the ability to import to Canada is truly groundbreaking for both companies."
"This agreement marks a meaningful step in Nuuvera executing its strategy to utilize its extensive international operational and production base, built upon a network of GMP-certified analytical testing, extraction, cannabinoid purification and product formulation facilities to enhance Canada's standing as a global leader in this important, emerging sector," said Lorne Abony, chief executive officer of Nuuvera. "This agreement is prescient and truly groundbreaking in leading the way to providing the best quality and variety of cannabis products to Canadians and in demonstrating Canadian foresight and leadership in setting the standard for cannabis-related health remedies globally."
Under the LOI terms, Nuuvera will import to Canada Isodiol's CBD isolate and conduct analytical testing in its Toronto-area laboratory to ensure that the product conforms to Isodiol's rigorous product specifications. Nuuvera intends, ultimately, to import up to 30,000 kilograms of CBD isolate per month for the purposes of research and development, product formulation, and production of pharma-grade derivative products. Through its licensed subsidiaries, Nuuvera intends to then sell such products in Canada and via export to appropriately licensed international medical cannabis jurisdictions.
Upon successful initial import and product testing, Nuuvera and Isodiol intend to execute a definitive supply agreement, the terms of which are already substantively agreed upon. The activities contemplated by the LOI remain subject to applicable regulatory approvals, including those from Health Canada and the TSX Venture Exchange.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of plus-99-per-cent-pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.
About Nuuvera Holdings Ltd.
Nuuvera Holdings is a global cannabis company founded on Canadian principles and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical-grade cannabis in legalized markets. Through its subsidiaries, ARA -- Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a dealer licence (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a licensed producer of medical marijuana under the ACMPR (Access to Cannabis for Medical Purposes Regulations) and has recently received its letter to build approval.
We seek Safe Harbor.
$ISOLF News out
ISODIOL INTERNATIONAL INC. ANNOUNCES LETTER OF INTENT TO IMPORT 99%+ PURE PHARMA-GRADE CANNABIDIOL TO CANADA FROM U.K. WITH NUUVERA
Isodiol International Inc. has signed a letter of intent with Nuuvera Holdings Ltd.
Isodiol and Nuuvera have agreed to import plus-99-per-cent-pure, bioactive pharma-grade cannabidiol isolate into Canada from Isodiol's GMP-certified production facility in the United Kingdom. The product, certified as a pharmaceutical grade, will be imported into Canada through Nuuvera's subsidiary, ARA -- Avanti Rx Analytics Inc., a Health Canada GMP-certified laboratory holding a dealer licence under the Narcotic Control Regulations and Office of Controlled Substances.
"Since establishing Isodiol, we have focused on developing and marketing the highest-quality, raw material for use in a range of proprietary, pharma-grade nutritional and health-related remedies," said Isodiol chief executive officer Marcos Agramont. "We are very pleased that our new partner, Nuuvera, which brings to the table extensive knowledge and expertise in the fields of quality control, cannabis extraction, purification, product development and R&D, shares Isodiol's vision for an industry built upon quality, consistency, safety and ultimately, efficacy. Isodiol and Nuuvera are at the global forefront of innovation in the cannabis industry, and the ability to import to Canada is truly groundbreaking for both companies."
"This agreement marks a meaningful step in Nuuvera executing its strategy to utilize its extensive international operational and production base, built upon a network of GMP-certified analytical testing, extraction, cannabinoid purification and product formulation facilities to enhance Canada's standing as a global leader in this important, emerging sector," said Lorne Abony, chief executive officer of Nuuvera. "This agreement is prescient and truly groundbreaking in leading the way to providing the best quality and variety of cannabis products to Canadians and in demonstrating Canadian foresight and leadership in setting the standard for cannabis-related health remedies globally."
Under the LOI terms, Nuuvera will import to Canada Isodiol's CBD isolate and conduct analytical testing in its Toronto-area laboratory to ensure that the product conforms to Isodiol's rigorous product specifications. Nuuvera intends, ultimately, to import up to 30,000 kilograms of CBD isolate per month for the purposes of research and development, product formulation, and production of pharma-grade derivative products. Through its licensed subsidiaries, Nuuvera intends to then sell such products in Canada and via export to appropriately licensed international medical cannabis jurisdictions.
Upon successful initial import and product testing, Nuuvera and Isodiol intend to execute a definitive supply agreement, the terms of which are already substantively agreed upon. The activities contemplated by the LOI remain subject to applicable regulatory approvals, including those from Health Canada and the TSX Venture Exchange.
About Isodiol International Inc.
Isodiol International is the market leader in pharmaceutical-grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of plus-99-per-cent-pure, bioactive pharmaceutical-grade cannabinoids, microencapsulations and nanotechnology for the highest-quality consumable and topical skin care products.
About Nuuvera Holdings Ltd.
Nuuvera Holdings is a global cannabis company founded on Canadian principles and built with the whole world in mind. Nuuvera is currently working with partners in Germany, Israel and Italy, and is exploring opportunities in several other countries, to develop commercial production and global distribution of medical-grade cannabis in legalized markets. Through its subsidiaries, ARA -- Avanti Rx Analytics Inc. and Avalon Pharmaceutical Inc., Nuuvera holds a dealer licence (GMP) under the Narcotic Control Regulations and Office of Controlled Substances. Nuuvera is currently in the final stages of the Health Canada review process to become a licensed producer of medical marijuana under the ACMPR (Access to Cannabis for Medical Purposes Regulations) and has recently received its letter to build approval.
We seek Safe Harbor.
$ISOLF News just out.
VANCOUVER, British Columbia, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE:ISOL) (OTC:ISOLF) (FSE:LB6A.F) (the “Company” or “Isodiol”), a global bioactive phytoceutical innovator specializing in the development of pharmaceutical and wellness products, is pleased to announce Be Tru Organics™ has signed a distribution agreement with United Natural Foods Inc (UNFI), the largest publicly traded wholesale distributor to the natural, organic and specialty industry in the United States and Canada.
With their distribution centers in the US and Canada, UNFI excels in the distribution of natural and organic foods and wellness products by fulfilling the highest standards for quality, consistency, product assortments, and dependability. Specifically, UNFI provides and delivers products for grocery, produce, health and beauty, bakery, and more.
“UNFI been recognized as one of America’s best managed companies, and with the continuous growth in the natural product industry, we are very excited about the opportunities this presents for Be Tru,” said CEO of Isodiol, Marcos Agramont. “UNFI has a very diversified sales base including natural product superstores, conventional supermarket chains, and independent health food retailers, giving consumers plenty of access to Be Tru products.”
“UNFI’s track record speaks for itself, and we are very pleased to be moving forward with this distribution agreement,” added Keith Gordon, CEO of Be Tru. “UNFI will be instrumental in introducing this brand to mainstream America and will allow Be Tru to continue growing and we look forward to the additional opportunities this agreement will present.”
For more information on Isodiol, please visit www.isodiol.com
For more information on Be Tru Organics™, please visit www.betruorganics.com
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
Join Us On Facebook: https://www.facebook.com/isodiol/
Twitter:@isodiol
ON BEHALF OF THE BOARD
Marcos Agramont, CEO & Director
INVESTOR RELATIONS:
Ir@isodiol.com
www.isodiol.com
MEDIA CONTACT:
Carrie Booze
North 6th Agency
212-334-9753 ext.142
Isodiol@n6a.com
$ISOLF has just done a deal with Kathy Irelands company.
ISODIOL INTERNATIONAL INC. SIGNS LICENSING AGREEMENT WITH LEVEL BRANDS INC. AND ITS CHAIRMAN EMERITUS AND CHIEF BRAND STRATEGIST KATHY IRELAND
Isodiol International Inc. has entered into a licensing agreement with Level Brands Inc., an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses.
Under the agreement, Isodiol will work with Level Brands to develop consumer products for its business units, kathy irelandtrademark Health & Wellness and Ireland Men One (I'M1), the company's lifestyle brand for men. Encore Endeavor One (EE1), Level Brands' corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines.
"We look forward to benefitting from Kathy Ireland's proven track record in product strategy and marketing," said Marcos Agramont, President of Isodiol. "Ms. Ireland has an uncanny sense of her consumers' tastes and needs, which has led to their extraordinary loyalty and confidence in her products. Having brought over 17,000 diverse and popular products to market, she has captured the hearts and minds of millions of customers who actively and consistently support her brands. Ms. Ireland will bring tremendous energy into this burgeoning field, and we are eager to work with her and the incredible team assembled at Level Brands."
"Isodiol is an innovative, progressive and pioneering company," said Kathy Ireland, Level Brands' Chairman Emeritus and Chief Brand Strategist. "Their success in CBD products derived from hemp are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skincare, nano-mist and functional beverages. One of the many responsibilities in this new venture is, for me personally, to serve as Educator in Chief about cannabidiol, and how it is used in Isodiol. This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It's ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever. This is the second product for kathy irelandtrademark Health & Wellness, licensed by Level Brands, and we welcome the Isodiol team to our family at Level."
"Level Brands is committed to exploring new and cutting-edge technologies and products and bringing them to the American market," says Martin A. Sumichrast, CEO of Level Brands'. "Isodiol is a pioneer and a leader in the commercialization of a 99%+ pure, Bioactive pharmaceutical-grade cannabinoid products derived from the hemp plant. We are excited to work with Isodiol on developing the highest quality hemp derivatives-based consumable and topical skin care products for kathy irelandtrademark Health & Wellness and I'M1."
kathy irelandtrademark Health & Wellness, I'M1 and EE1 are led in marketing and creative by Stephen Roseberry, President and Chief Marketing Officer of kathy irelandtrademark Worldwide (kiWWtrademark), together with kiWWtrademark's Global Creative Director, Jon Carrasco. I'M1 was co-founded by Kathy Ireland and Tommy Meharey - Marine, millennial father, global fashion model, concert producer, Vice President of kathy irelandtrademark Weddings & Resorts, as well as the youngest Board of Directors member of kathy irelandtrademark Worldwide. EE1 was co-founded by Ireland and Nic Mendoza, heir to a family legacy with generations of extraordinary musical success. Mr. Mendoza is a certified sound specialist, with an emphasis on live performance, having toured with artists as diverse as Janet Jackson and Robin Thicke, and a producer of albums and musical theater.
The new Isodiol kathy irelandtrademark Health & Wellness and I'M1 products are expected to debut in mid to late Spring 2018 and be available online and in select retail stores. Level Brands is committed to social responsibility, with each partner, client, and licensee supporting its Millennium Development Goals to improve the condition of lives around the world. Through this licensing agreement, Isodiol has made a corporate culture and financial commitment to support these goals with an emphasis on health and wellness.
Level Brands will receive an initial US$2 million payment in the form of Isodiol shares and initial cash payments of US$62,500 each due at execution of the licensing agreement and on June 30, 2018 . During the term of the agreement Level will also receive US$750,000 per quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The release of Isodiol shares to Level shall be subject to a rolling thirty-month escrow following each issuance. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties intend to finalize all points of the negotiations no later than January 31, 2018.
About Isodiol International Inc. (www.Isodiol.com)
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.
Great news for $ISOLF this morning!
ISODIOL INTERNATIONAL INC. SIGNS LICENSING AGREEMENT WITH LEVEL BRANDS INC. AND ITS CHAIRMAN EMERITUS AND CHIEF BRAND STRATEGIST KATHY IRELAND
Isodiol International Inc. has entered into a licensing agreement with Level Brands Inc., an innovative marketing and licensing company that provides bold, unconventional and socially responsible branding for leading businesses.
Under the agreement, Isodiol will work with Level Brands to develop consumer products for its business units, kathy irelandtrademark Health & Wellness and Ireland Men One (I'M1), the company's lifestyle brand for men. Encore Endeavor One (EE1), Level Brands' corporate brand management and producer of experiential entertainment events, will provide strategic advisory services for the new wellness product lines.
"We look forward to benefitting from Kathy Ireland's proven track record in product strategy and marketing," said Marcos Agramont, President of Isodiol. "Ms. Ireland has an uncanny sense of her consumers' tastes and needs, which has led to their extraordinary loyalty and confidence in her products. Having brought over 17,000 diverse and popular products to market, she has captured the hearts and minds of millions of customers who actively and consistently support her brands. Ms. Ireland will bring tremendous energy into this burgeoning field, and we are eager to work with her and the incredible team assembled at Level Brands."
"Isodiol is an innovative, progressive and pioneering company," said Kathy Ireland, Level Brands' Chairman Emeritus and Chief Brand Strategist. "Their success in CBD products derived from hemp are 99%+ pure, bioactive and pharmaceutical grade. The products include body balm, tincture, skincare, nano-mist and functional beverages. One of the many responsibilities in this new venture is, for me personally, to serve as Educator in Chief about cannabidiol, and how it is used in Isodiol. This company is leading the strategy of appropriate uses of hemp derivatives, and Isodiol products are free of THC. It's ironic that people find controversy in the powerfully useful hemp plant. Without THC, hemp has many natural and important uses, which are beneficial in countless ways. We need people to please understand, that hemp, without THC, is similar to a grape without fermentation. What the Isodiol team has done is, bring the best qualities of hemp-derived CBD to the market without any psychotropic element, whatsoever. This is the second product for kathy irelandtrademark Health & Wellness, licensed by Level Brands, and we welcome the Isodiol team to our family at Level."
"Level Brands is committed to exploring new and cutting-edge technologies and products and bringing them to the American market," says Martin A. Sumichrast, CEO of Level Brands'. "Isodiol is a pioneer and a leader in the commercialization of a 99%+ pure, Bioactive pharmaceutical-grade cannabinoid products derived from the hemp plant. We are excited to work with Isodiol on developing the highest quality hemp derivatives-based consumable and topical skin care products for kathy irelandtrademark Health & Wellness and I'M1."
kathy irelandtrademark Health & Wellness, I'M1 and EE1 are led in marketing and creative by Stephen Roseberry, President and Chief Marketing Officer of kathy irelandtrademark Worldwide (kiWWtrademark), together with kiWWtrademark's Global Creative Director, Jon Carrasco. I'M1 was co-founded by Kathy Ireland and Tommy Meharey - Marine, millennial father, global fashion model, concert producer, Vice President of kathy irelandtrademark Weddings & Resorts, as well as the youngest Board of Directors member of kathy irelandtrademark Worldwide. EE1 was co-founded by Ireland and Nic Mendoza, heir to a family legacy with generations of extraordinary musical success. Mr. Mendoza is a certified sound specialist, with an emphasis on live performance, having toured with artists as diverse as Janet Jackson and Robin Thicke, and a producer of albums and musical theater.
The new Isodiol kathy irelandtrademark Health & Wellness and I'M1 products are expected to debut in mid to late Spring 2018 and be available online and in select retail stores. Level Brands is committed to social responsibility, with each partner, client, and licensee supporting its Millennium Development Goals to improve the condition of lives around the world. Through this licensing agreement, Isodiol has made a corporate culture and financial commitment to support these goals with an emphasis on health and wellness.
Level Brands will receive an initial US$2 million payment in the form of Isodiol shares and initial cash payments of US$62,500 each due at execution of the licensing agreement and on June 30, 2018 . During the term of the agreement Level will also receive US$750,000 per quarter in the form of Isodiol shares and a 3% royalty on all gross sales of branded products. The release of Isodiol shares to Level shall be subject to a rolling thirty-month escrow following each issuance. The contract term is for an initial five years. Marketing materials were designed and filmed in December 2017 and both parties intend to finalize all points of the negotiations no later than January 31, 2018.
About Isodiol International Inc. (www.Isodiol.com)
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products. Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio, and aggressively continuing international expansion into Latin America, Asia and Europe.
Great to see $ISOLF rise from the ashes today
Great day for $ISOLF today, here's the news from earlier for those of you who may have missed it.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2552055&symbol=ISOL®ion=C
$ISOLF is now involved in California.
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2552055&symbol=ISOL®ion=C
Its starting to look much better now, nice to see it finally back in the green today. This company will have its day in the sun again, they are very well cashed up right now so who knows what moves they could be planning on next.
$ISOLF is now involved in California!
https://www.stockwatch.com/News/Item.aspx?bid=Z-C%3aISOL-2552055&symbol=ISOL®ion=C
This is huge for $ISOLF! California Love!
ISODIOL INTERNATIONAL INC. ANNOUNCES NON-BINDING AGREEMENT WITH LICENSED CALIFORNIA MARIJUANA MANUFACTURER FOR POT-O-COFFEE
Isodiol International Inc. has signed a non-binding agreement with a California-based licensed marijuana manufacturer for its Pot-O-Coffee brands.
The manufacturer has received its adult-use temporary recreational manufacturing license and is now in the final weeks of setting up their facility to produce the Pot-O-Coffee product line. Upon completion of this facility, the Company will move forward with commercialization and anticipates this date to be within the next 6-8 weeks.
"This is another very exciting step in our ongoing efforts with the Pot-O-Coffee brand," said Marcos Agramont, CEO of Isodiol. "With the recent legalization of recreational cannabis in California, we are continuing to position the Company to capture market share in this large and growing market opportunity."
Additional information on the manufacturer will be provided upon execution of the definitive agreement, which is anticipated in the coming weeks.
About Isodiol International Inc.
Isodiol International Inc. is the market leader in pharmaceutical grade phytochemical compounds and the industry leader in the manufacturing and development of phytoceutical consumer products.
Isodiol is the pioneer of many firsts for the cannabis industry including commercialization of 99%+ pure, bioactive pharmaceutical grade cannabinoids, micro-encapsulations, and nanotechnology for the highest quality consumable and topical skin care products.
Isodiol's growth strategy includes the development of over-the-counter and pharmaceutical drugs, expanding its phytoceutical portfolio and will aggressively continue international expansion into Latin America, Asia and Europe.
We seek Safe Harbor.
Its great to see $ISOLF part of this Brand New ETF that just started today.
http://www.mjxetf.com/fund/#quarter
This ETF just started up today, someone mentioned that $ISOLF may be included in this. Has anyone else heard this?
ETF Managers Group Announces MJX Live for Trading on the NYSE
2017-12-26 09:53 ET - News Release
SUMMIT, N.J. -- (Business Wire)
ETF Managers Group LLC (“ETFMG”) announced today that MJX, the ETFMG Alternative Harvest ETF is live and available for trading on the NYSE Arca. This fund is one of the first of its kind available to U.S. investors allowing them access to a unique sector in this rapidly evolving market. MJX is designed to replicate the Prime Alternative Harvest Index, which tracks companies likely to benefit from the increasing global acceptance of various uses of the cannabis plant. This includes treatments from innovative medicinal breakthroughs involving the plant’s unique properties – the result of years of significant research by the global biotech and pharmaceutical community.
Sam Masucci, Founder & CEO of ETF Managers Group said: “As an ETF issuer we are excited about opportunities for innovation, the chance to give investors exposure to new markets and doing our part to impact the continued evolution of the ETF industry by meeting the appetite of investor interest.”
The ETFMG Alternative Harvest ETF seeks to provide investment results that, before fees and expenses, correspond generally to the total return performance of the Prime Alternative Harvest Index. For more information on the Fund please visit: www.MJXetf.com.
Effective December 26th, 2017, the Fund’s name (previously the Tierra XP Latin America Real Estate ETF, ticker symbol: LARE) has changed to the ETFMG Alternative Harvest ETF, ticker symbol: MJX. The Fund’s underlying index has been changed to the Prime Alternative Harvest Index which is provided by Prime Indexes and will be calculated by Solactive AG. Information about the index can be found by visiting www.primeindexes.com.
About ETF Managers Group (ETFMG)
ETFMG is a leading Exchange Traded Funds (ETF) private label services company. ETFMG offers a full range of ETF product services to the asset management community including commodity pool ETPs as well as both active and passive ETF funds. The services provided include product operations, regulatory, financial and compliance management. ETF Managers Group offers active marketing and dedicated wholesale services for all ETF product types. For more information on ETF Managers Group visit www.etfmg.com.
$ISOLF is having another amazing morning so far.
$ISOLF is looking strong once again today
Nice to see $ISOLF having another positive day once again.